Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update
– Patient screening in Phase 2a study of simufilam in TSC-related epilepsy expected to begin by Q1 2027, following recent lift of FDA clinical hold – Recent publication in Cells1 provides new insights into simufilam’s potential mechanism of action AUSTIN, Texas, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ:FLNA, "Filana Therapeutics", the "Company")) today reported financial results for the third quarter ended September 30, 2026. "Simufilam has the potential to make a meaningful difference for patients with TSC-related epilepsy. We began working toward activating clinical study sites as soon as FDA lifted the clinical hold in September. Patient screening is expec